Dalmane
(Flurazepam)Phase 1Small molecule
Dalmane is one of 37 small molecule programs targeting Insomnia. It is currently in Phase 1.
1
Indications
2
Total Trials
0
Active Trials
36
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
153 competitors in Insomnia
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsPhase 3
Elavil
AstraZenecaPhase 3
Neurontin
VViatris Specialty LLC
Phase 3
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Hetlioz
VVanda Pharmaceuticals
Phase 3
Gaboxadol
LundbeckPhase 3
Volinanserin
SanofiPhase 3
Prosom
AAbbott
Phase 3
Nitrazepam
AstellasPhase 3
Org 50081
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
DALMANE
NDA NDA016721
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Flurazepam. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- VValeant Pharmaceuticals